A clinical-stage psychedelics company developing therapeutics for addiction, PTSD and depression
An alcohol use disorder franchise across the UK, Europe and the U.S. A de novo engine of proprietary new medicines.
Two complementary development strategies
Scientific leadership: Professor David Nutt, Chief Scientific Officer, and Edmond J Safra Professor of Neuropsychopharmacology at Imperial College London.
Value-added medicines: the AUD franchise
Differentiated ketamine- and esketamine-based treatments built on established pharmacology, clinical experience and regulatory precedent.
Value creation | Nearer-term clinical and regulatory catalysts
De novo drug development: the engine
Creating proprietary new chemical entities (NCEs) with composition-of-matter filings in high-burden addiction and psychiatric disorders.
Value creation | Longer-duration IP and early-stage upside
The SVN-001 Phase 3 is co-funded by the National Institute for Health and Care Research (NIHR), the Medical Research Council (MRC) and Solvonis, and sponsored by the University of Exeter. The U.S. National Institute on Drug Abuse (NIDA) funds the SVN-015 evaluation, which has advanced into further NIDA-funded studies.
Five programmes: an alcohol use disorder franchise and a de novo engine
SVN-001, SVN-002, SVN-015 and SVN-114 are investigational. None has been approved by any regulator, and their safety and efficacy have not been established.
people aged 15+ with severe AUD in the UK and EU4 (Company estimate)
people aged 12+ with past-year moderate-to-severe AUD in the U.S. (2024)
people with AUD worldwide receive treatment
of U.S. overdose deaths (2021 to mid-2024) involved stimulants
Epidemiological estimates, not treated or addressable patients. UK and EU4 (France, Germany, Italy, Spain) figure is a Company estimate (July 2026); U.S. figure: SAMHSA, 2024 NSDUH. Treatment rate: Mekonen et al., Addiction 2021. Stimulants: Tanz et al., MMWR 2025.
Pharma is paying for psychedelic and rapid-acting neuropsychiatry assets
Pharma has paid billions for depression and PTSD. Solvonis has programmes in both, and a Phase 3 ketamine-based treatment in alcohol use disorder (AUD), where only 1 in 6 people receive treatment.
Sources: Eli Lilly, 11 September 2026 (completion) and 16 July 2026 (terms); Otsuka, 12 June 2026; AbbVie, 17 October 2025. Values include contingent consideration where stated. Dates are completion dates. Sector context; not valuation comparables.
Latest news
All newsStay informed
Updates on pipeline progress, white papers, events and team news. We will ask you to confirm your address by email.